MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.550
-0.030
-1.90%
After Hours: 1.550 0 0.00% 18:41 09/28 EDT
OPEN
1.570
PREV CLOSE
1.580
HIGH
1.590
LOW
1.530
VOLUME
714.42K
TURNOVER
--
52 WEEK HIGH
3.690
52 WEEK LOW
1.360
MARKET CAP
118.15M
P/E (TTM)
-1.2891
1D
5D
1M
3M
1Y
5Y
Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial.
Benzinga · 09/13 13:41
BRIEF-Additional Data from Hepion Pharmaceuticals' Phase 2a Trial Further Strengthens CRV431 Clinical Profile
reuters.com · 09/13 13:23
Hepion Pharmaceuticals Highlights Data From Phase 2a 'AMBITION' Trial; Says, As Previously Reported, All Primary Endpoints Were Met
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
Benzinga · 09/13 12:14
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 09/13 12:10
Additional Data from Hepion Pharmaceuticals’ Phase 2a ‘AMBITION’ Trial Further Strengthens CRV431 Clinical Profile and Paves Way for Initiation of Phase 2b ‘ASCEND-NASH’ Clinical Program
Pro-C3 and ALT reductions point to anti-inflammatory and antifibrotic effects of CRV431PK-PD models successfully predict early reductions in Pro-C3 and ALTHepion’s proprietary AI-POWR™ and machine learning accurately predict CRV431 respondersAnti-fibrotic ...
GlobeNewswire · 09/13 12:00
21 Stocks Moving in Monday's Pre-Market Session
Gainers Itamar Medical Ltd. (NASDAQ: ITMR) rose 43% to $29.52 in pre-market trading. Zoll Medical said it has signed an agreement to acquire Itamar Medical for $31 per ADS in cash.
Benzinga · 09/13 11:07
Why Are Hepion Pharma Shares Moving Higher Premarket Monday?
Benzinga · 09/13 09:56
Hepion Pharmaceuticals Schedules Conference Call To Review Data From Phase 2a 'AMBITION' Clinical Trial Of CRV431 in NASH
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
Benzinga · 09/10 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HEPA. Analyze the recent business situations of Hepion Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HEPA stock price target is 6.33 with a high estimate of 8.00 and a low estimate of 5.00.
High8.00
Average6.33
Low5.00
Current 1.550
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 58
Institutional Holdings: 10.77M
% Owned: 14.13%
Shares Outstanding: 76.23M
TypeInstitutionsShares
Increased
12
1.22M
New
10
2.75M
Decreased
12
491.25K
Sold Out
6
687.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.50%
Pharmaceuticals & Medical Research
-1.90%
Key Executives
Non-Executive Chairman/Independent Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Other
Todd Hobbs
Independent Director
Thomas Adams
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Petrus Wijngaard
No Data
About HEPA
Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups.

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.